SymBio Pharmaceuticals : News：News & Topics

HOME
News&Topics

News & Topics

2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2016.12.19: Analyst Report: Shared Research updates the report
2016.12.19: Approval in Japan of the Anti-cancer Drug TREAKISYM® for the Additional Indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
2016.12.06: Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting
2016.11.22: Initiation of Patient Enrollment in the Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
2016.11.14: Notice of Shareholder Voting Results for the Extraordinary Shareholders' Meeting
2016.11.11: Analyst Report: Shared Research updates the report
2016.11.11: Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.11.11: Notice concerning Non-operating Expenses
2016.10.20: Information on The Extraordinary Shareholders' Meeting: Updated the Page
2016.10.03: Notice concerning the Change in Major and Largest Shareholder among the Company's Major Stockholders
2016.09.28: Approval in Japan of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg
2016.09.27: Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes
2016.09.15: Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
2016.09.15: Notice concerning Partial Amendment to the Articles of Incorporation
2016.09.12: Analyst Report: Shared Research updates the report
2016.08.26: Approval of the Anti-cancer Drug TREAKISYM® for the Additional Indication of Chronic Lymphocytic Leukemia
2016.08.04: Analyst Report: Shared Research updates the report
2016.08.04: Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.08.04: Notice Concerning Non-operating Expenses
2016.07.19: Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3 Trial of IV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS)
2016.06.16: Corporate governance policies
2016.06.14: Onconova Announces Presentation of Clinical Data from Oral Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting
2016.06.13: Analyst Report: Shared Research updates the report
2016.06.13: Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
2016.06.08: Notice concerning the Change of Major Shareholder
2016.06.07: Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting
2016.06.02: Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting
2016.05.30: Notice concerning the Change of Major Shareholder
2016.05.24: Notice concerning the Change of Major Shareholder
2016.05.20: Notice concerning Cancellation of the Extraordinary Shareholders' Meeting on July 15, 2016 and Cancellation of the Record Date therefor
2016.05.19: Notice concerning the Change of Major and Largest Shareholder among the Company's Major Stockholders
2016.05.11: SymBio Announces Incorporation of its U.S. Subsidiary
2016.05.10: Analyst Report: Shared Research updates the report
2016.05.10: Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
2016.05.10: Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.05.10: Notice Concerning Non-operating Expenses
2016.04.22: Completion of Payment for Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
2016.04.14: Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2016.04.14: Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2016.04.06: Analyst Report: Shared Research updates the report
2016.04.06: Notice of the Issuance of and the Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
2016.03.31: (Correction) Notice concerning partial correction to the "Notice of Appointment of Directors"
2016.03.31: Notice of Shareholder Voting Results for the 11th Ordinary General Meeting of Shareholders
2016.03.30: Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
2016.03.30: Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
2016.03.30: Notice of Appointment of Directors
2016.03.23: Analyst Report: Edison updates the report
2016.03.21: Analyst Report: Edison updates the report
2016.03.17: Analyst Report: Shared Research updates the report
2016.03.11: Information on Shareholders' Meeting: Updated the Page
2016.03.10: Notice concerning Partial Amendment to the Articles of Incorporation and Nomination of Director Candidates
2016.03.10: Onconova Announces Publication of Results from the ONTIME Trial for rigosertib in MDS
2016.02.10: Analyst Report: Shared Research updates the report
2016.02.10: SymBio's Long Range Plan: FY2016 to FY2018
2016.02.10: Summary of Financial Statements for the Fiscal Year Ended December 31, 2015[Japanese GAAP] (Non-consolidated)
2016.02.10: Notice Concerning Non-operating Expenses
2016.02.08: SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
2016.02.04: Assessment Status of Bendamustine in Europe